Replies to post #194780 on Biotech Values

[DewDiligence]

FDA reviewing NVS’ 351(k) submission for Neulasta FoB:

https://www.novartis.com/news/media-releases/regulatory-submission-sandoz-proposed-biosimilar-pegfilgrastim-accepted-fda

NVS seeks FDA approval of the FoB for all of Neulasta’s approved indications (as was the case with NVS’ Zarxio FoB for Neupogen).

[DewDiligence]

AMGN—2Q16 Neupogen sales fell 23% YoY—due, in part, to the launch of NVS’ Zarxio:

http://finance.yahoo.com/news/amgen-reports-second-quarter-2016-200100033.html